- Home
- » Tags
- » Glatiramer acetate
Top View
- Multiple Sclerosis Agents
- Comparative Efficacy of First-Line Natalizumab Vs IFN-Β Or Glatiramer Acetate in Relapsing MS Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Et Al
- Tumefactive Demyelinating Lesions in Patients with Relapsing Remitting
- Clinical Policy: Ozanimod (Zeposia)
- ZEPOSIA® (Ozanimod) Capsules, for Oral Use Liver Function Tests Before Initiating ZEPOSIA (5.3) Initial U.S
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08/16 Last Review Date: 08/17 Revision Log
- The Effectiveness of Interferon Beta Versus Glatiramer Acetate and Natalizumab Versus Fingolimod in a Polish Real-World Population
- "Alemtuzumab" in the Treatment of Multiple Sclerosis
- IMPORTANT SAFETY INFORMATION Do Not Take GLATIRAMER ACETATE INJECTION If You Are Allergic to Glatiramer Acetate Or Mannitol
- P R I M E R Advances in Multiple Sclerosis
- Glatiramer Acetate Autoimmune Encephalomyelitis by Oral Th2 Bias
- How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis
- Multiple Sclerosis: Gilenya (Fingolimod) Step Edit Policy
- Transtentorial Herniation from Tumefactive Multiple Sclerosis Mimicking Primary Brain Tumor Kunal Vakharia, Haris Kamal1, Gursant S
- Immunomodulation of Glatiramer Acetate in Multiple Sclerosis Chunhua Chen* Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA
- Disease-Modifying Therapies
- Beta Interferons and Glatiramer Acetate for Treating Multiple Sclerosis
- Ozanimod for Relapsing Remitting Multiple Sclerosis
- For Multiple Sclerosis
- Real-World Demographics, Clinical Characteristics and Treatment
- Multiple Sclerosis Agents
- Cost-Effectiveness of Delayed-Release Dimethyl
- The Heritage of Glatiramer Acetate and Its Use in Multiple Sclerosis
- Complete Issue (PDF)
- Prior Authorization Multiple Sclerosis – Glatiramer Products
- Comparative Effectiveness of Early Natalizumab Treatment in JC Virus–Negative Relapsing-Remitting Multiple Sclerosis
- Physicochemical and Biological Examination of Two Glatiramer Acetate Products
- Multiple Sclerosis Therapy – Oral and Subcutaneous
- A 12-Month, Randomized, Rater-Blinded, Glatiramer- Acetate
- 3.2.1 Fingolimod and Tumefactive Lesions
- Cost-Effectiveness of Teriflunomide (Aubagio®) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis
- Mavenclad® (Cladribine) P&T Approval Date 11/2019, 1/2021 Effective Date 4/1/2021; Oxford Only: 4/1/2021
- Risk Assessment and Risk Mitigation Review(S)
- Mavenclad- ARIZONA
- Glatiramer Acetate Reduces Th-17 Inflammation and Induces
- Alemtuzumab Versus Generic Glatiramer Acetate in Patients with Relapsing Forms of Multiple Sclerosis: a Cost-Effectiveness Study in the United States
- Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
- Dimethyl Fumarate with Glatiramer Acetate Or Interferon-Beta for Treating Multiple Sclerosis
- Gilenya® (Fingolimod)
- Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
- Demyelination Arrest and Remyelination Induced by Glatiramer Acetate Treatment of Experimental Autoimmune Encephalomyelitis
- INJECTABLE DRUGS Avonex, Rebif (Interferon Beta-1A); Plegridy
- An Atypical Case of Astrocytoma in a Patient with Relapsing–Remitting Multiple Sclerosis
- Glatiramer Acetate) Policy Number: C10270-A
- Differential Expression of Neurotrophic and Gliotrophic Factors
- Glatiramer Acetate
- COPAXONE® Safely and Effectively